Shasun Chemicals and Drugs Ltd. (SCDL), the Chennai-based pharma major focused on manufacture of finished dosage, APIs and intermediates, has decided to designate N Govindarajan as the CEO & managing director with immediate effect. The promoter directors who were the managing & joint managing directors would continue as whole time directors, according to the decision of the board of directors.
Govindarajan was holding the charge of CEO and has been instrumental in Shasun's entry into formulations, expansion of the Ibuprofen capacity and manufacture of multi-product. Govindarajan was also instrumental for the successful scale-up of key custom synthesis projects to the commercial level by developing relationships with MNC's. He started career with Shasun as a general manager - R&D, project and planning in January 2000. Within 18 months, he rose to the position of the vice president - R&D.
During his tenure of operation as CEO, Shasun made its maiden acquisition of business and assets of UK based Rhodia Pharma through the wholly owned subsidiary Shasun Pharma Solutions Ltd (SPSL), resulting a global presence in APIs, custom synthesis and contract manufacturing.